We research and develop biopharmaceutical products, including those based on our
patented DNA delivery technologies, for the prevention and treatment of serious
or life-threatening diseases.
We currently have three active, independent or partnered, development programs
in the area of infectious disease comprised of:
* An ongoing Phase 3 trial of ASP0113 for prevention of cytomegalovirus, or
CMV, reactivation in hematopoietic stem cell transplant, or HCT,
recipients in collaboration with Astellas Pharma Inc., or Astellas.
Astellas has completed enrollment in the Phase 3 clinical trial and
expects top-line data to be available in the first quarter of 2018.
* An ongoing Phase 2 trial of VCL-HB01, our Vaxfectin®-formulated
therapeutic DNA vaccine for reduction of lesion recurrences caused by
herpes simplex virus type 2, or HSV-2, infection.